Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected

A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected The paradigm of targeted therapy was pioneered for chronic myeloid leukemia (CML). The advent of tyrosine kinase inhibitors (TKIs) has led to marked improvements in responses and overall survival; however, there is still a subset of patients that are either resistant through a multitude of mechanisms or intolerant to standard TKI therapy. Omacetaxine mepesuccinate (omacetaxine), a semisynthetic purified homoharringtonine compound, has been studied for over 40 years and was approved in 2012 by the Food and Drug Administration (FDA) for patients with CML refractory or intolerant to two or more TKIs. Omacetaxine has a novel mechanism of action—inhibition of protein synthesis, which does not overlap with kinase inhibition. Multiple studies have demonstrated that omacetaxine can achieve responses in heavily treated patients with either chronic-phase or accelerated-phase CML, regardless of the presence of mutations in the tyrosine kinase domain. This review will outline the tortuous story of omacetaxine, including preclinical and clinical studies of homoharringtonine, current indications, and management guidelines. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected

Winer, Eric; DeAngelo, Daniel
Oncology and Therapy , Volume 6 (1) – Mar 15, 2018
Download PDF
12 pages

Loading next page...
 
/lp/springer-journals/a-review-of-omacetaxine-a-chronic-myeloid-leukemia-treatment-qFcipcTRir
Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-018-0058-6
Publisher site
See Article on Publisher Site

Abstract

The paradigm of targeted therapy was pioneered for chronic myeloid leukemia (CML). The advent of tyrosine kinase inhibitors (TKIs) has led to marked improvements in responses and overall survival; however, there is still a subset of patients that are either resistant through a multitude of mechanisms or intolerant to standard TKI therapy. Omacetaxine mepesuccinate (omacetaxine), a semisynthetic purified homoharringtonine compound, has been studied for over 40 years and was approved in 2012 by the Food and Drug Administration (FDA) for patients with CML refractory or intolerant to two or more TKIs. Omacetaxine has a novel mechanism of action—inhibition of protein synthesis, which does not overlap with kinase inhibition. Multiple studies have demonstrated that omacetaxine can achieve responses in heavily treated patients with either chronic-phase or accelerated-phase CML, regardless of the presence of mutations in the tyrosine kinase domain. This review will outline the tortuous story of omacetaxine, including preclinical and clinical studies of homoharringtonine, current indications, and management guidelines.

Journal

Oncology and Therapy – Springer Journals

Published: Mar 15, 2018

References

  • Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome
    Daley, GQ; Van, Etten RA; Baltimore, D
  • Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
    Lugo, TG; Pendergast, AM; Muller, AJ; Witte, ON
  • Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia
    Warrell, RP; Coonley, CJ; Gee, TS
  • Continuous infusion homoharringtonine (NSC 141633) in refractory acute nonlymphocytic leukemia. An ECOG pilot study
    Stewart, JA; Cassileth, PA; Bennett, JM; O’Connell, MJ
  • Homoharringtonine is safe and effective for patients with acute myelogenous leukemia
    Feldman, E; Arlin, Z; Ahmed, T; Mittelman, A; Puccio, C; Chun, H
  • Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia
    Kantarjian, HM; Keating, MJ; Walters, RS; Koller, CA; McCredie, KB; Freireich, EJ
  • Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia
    Feldman, EJ; Seiter, KP; Ahmed, T; Baskind, P; Arlin, ZA
  • Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase
    O’Brien, S; Kantarjian, H; Keating, M; Beran, M; Koller, C; Robertson, LE
  • Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia
    O’Brien, S; Kantarjian, H; Koller, C; Feldman, E; Beran, M; Andreeff, M
  • Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia
    O’Brien, S; Talpaz, M; Cortes, J; Shan, J; Giles, FJ; Faderl, S
  • Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia
    Kantarjian, HM; Talpaz, M; Smith, TL; Cortes, J; Giles, FJ; Rios, MB
  • A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804
    Stone, RM; Donohue, KA; Stock, W; Hars, V; Linker, CA; Shea, T
  • Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase
    O’Brien, S; Giles, F; Talpaz, M; Cortes, J; Rios, MB; Shan, J
  • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
    Kantarjian, H; Sawyers, C; Hochhaus, A; Guilhot, F; Schiffer, C; Gambacorti-Passerini, C
  • Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
    Hughes, TP; Kaeda, J; Branford, S; Rudzki, Z; Hochhaus, A; Hensley, ML
  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    O’Brien, SG; Guilhot, F; Larson, RA; Gathmann, I; Baccarani, M; Cervantes, F
  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    Druker, BJ; Guilhot, F; O’Brien, SG; Gathmann, I; Kantarjian, H; Gattermann, N
  • Long-term outcomes of imatinib treatment for chronic myeloid leukemia
    Hochhaus, A; Larson, RA; Guilhot, F; Radich, JP; Branford, S; Hughes, TP
  • Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
    Hochhaus, A; O’Brien, SG; Guilhot, F; Druker, BJ; Branford, S; Foroni, L
  • Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
    Hochhaus, A; Kantarjian, HM; Baccarani, M; Lipton, JH; Apperley, JF; Druker, BJ
  • Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
    Kantarjian, H; Shah, NP; Hochhaus, A; Cortes, J; Shah, S; Ayala, M
  • Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
    Saglio, G; Kim, DW; Issaragrisil, S; Coutre, P; Etienne, G; Lobo, C
  • Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
    Brummendorf, TH; Cortes, JE; Souza, CA; Guilhot, F; Duvillie, L; Pavlov, D
  • Ponatinib in refractory Philadelphia chromosome-positive leukemias
    Cortes, JE; Kantarjian, H; Shah, NP; Bixby, D; Mauro, MJ; Flinn, I
  • Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
    Lipton, JH; Chuah, C; Guerci-Bresler, A; Rosti, G; Simpson, D; Assouline, S
  • Management of imatinib-resistant patients with chronic myeloid leukemia
    Bhamidipati, PK; Kantarjian, H; Cortes, J; Cornelison, AM; Jabbour, E
  • Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants
    Redaelli, S; Piazza, R; Rostagno, R; Magistroni, V; Perini, P; Marega, M
  • AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance
    O’Hare, T; Shakespeare, WC; Zhu, X; Eide, CA; Rivera, VM; Wang, F
  • BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia
    Zabriskie, MS; Eide, CA; Tantravahi, SK; Vellore, NA; Estrada, J; Nicolini, FE
  • Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors
    Eide, CA; O’Hare, T
  • Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors
    Patel, AB; O’Hare, T; Deininger, MW
  • Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia
    Barnes, DJ; Palaiologou, D; Panousopoulou, E; Schultheis, B; Yong, ASM; Wong, A
  • Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia
    Gandhi, V; Plunkett, W; Cortes, JE
  • U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome
    Gurel, G; Blaha, G; Moore, PB; Steitz, TA
  • Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice
    Chen, Y; Hu, Y; Michaels, S; Segal, D; Brown, D; Li, S
  • Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells
    Allan, EK; Holyoake, TL; Craig, AR; Jorgensen, HG
  • Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor
    Lindqvist, LM; Vikstrom, I; Chambers, JM; McArthur, K; Ann Anderson, M; Henley, KJ
  • Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP)
    Yinjun, L; Jie, J; Weilai, X; Xiangming, T
  • Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells
    Tong, H; Ren, Y; Zhang, F; Jin, J
  • Homoharringtonine contributes to imatinib sensitivity by blocking the EphB4/RhoA pathway in chronic myeloid leukemia cell lines
    Huang, BT; Zeng, QC; Zhao, WH; Tan, Y
  • U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia
    Alvandi, F; Kwitkowski, VE; Ko, CW; Rothmann, MD; Ricci, S; Saber, H
  • Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib
    Marin, D; Kaeda, JS; Andreasson, C; Saunders, SM; Bua, M; Olavarria, E
  • Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy
    Quintas-Cardama, A; Kantarjian, H; Garcia-Manero, G; O’Brien, S; Faderl, S; Estrov, Z
  • Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
    Cortes, J; Lipton, JH; Rea, D; Digumarti, R; Chuah, C; Nanda, N
  • Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
    Cortes, J; Digumarti, R; Parikh, PM; Wetzler, M; Lipton, JH; Hochhaus, A
  • Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors
    Nicolini, FE; Khoury, HJ; Akard, L; Rea, D; Kantarjian, H; Baccarani, M
  • Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: results with 24 months of follow-up
    Cortes, JE; Kantarjian, HM; Rea, D; Wetzler, M; Lipton, JH; Akard, L